Adaptive licensing US style: FDA proposes another expedited pathway for new drugs, this time for 'limited' use
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is moving forward with plans to create a new shortened regulatory pathway for drugs aimed at treating serious or life-threatening conditions for which there are unmet medical needs – permitting manufacturers to take a streamlined approach with shorter studies using smaller patient populations1.